Abstract 971P
Background
The growing demand for hepatic resection in elderly hepatocellular carcinoma (HCC) patients highlights the need to understand the impact of preoperative frailty on surgical outcomes. This multicenter retrospective cohort study aimed to investigate the association between frailty and short-term and long-term outcomes following hepatic resection in elderly HCC patients.
Methods
We conducted a multicenter retrospective cohort study on elderly patients (≥70 years) who underwent curative-intent hepatic resection for HCC at 10 Chinese hospitals in China from 2012 to 2021. Frailty was assessed using the Clinical Frailty Scale (CFS), with frailty defined as CFS ≥ 5. Primary outcomes included overall survival (OS) and recurrence-free survival (RFS); secondary outcomes encompassed postoperative 30-day morbidity, 30-day mortality, and 90-day mortality. We compared these outcomes between patients with and without preoperative frailty.
Results
Of the 488 elderly patients, 148 (30.3%) were considered frail. Frail patients experienced significantly higher postoperative 30-day morbidity (68.9% vs. 43.2%), 30-day mortality (4.1% vs. 0.6%), and 90-day mortality (6.1% vs. 0.9%) than non-frail patients (all P<0.05). During a median follow-up of 37.7 months (IQR: 20.4-57.8), frail patients demonstrated significantly worse median OS (41.6 months [95% CI, 32.0-51.2] vs. 69.7 months [95% CI, 55.6-83.8]) and RFS (27.6 months [95% CI, 23.1-32.1] vs. 42.7 months [95% CI, 34.6-50.8]) compared to non-frail patients (both P<0.01). Multivariate Cox-regression analysis revealed frailty as a significant predictor for OS (HR 1.61, 95% CI 1.22-2.13, P=0.001) and RFS (HR 1.32, 95% CI 1.03-1.70, P=0.028).
Conclusions
Frailty was significantly associated with adverse short-term and long-term outcomes in elderly HCC patients undergoing hepatic resection. Our findings suggest that frailty assessment should be incorporated into perioperative and postoperative prognosis evaluation, and particular attention should be given to frail elderly patients undergoing this procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China; Dawn Project Foundation of Shanghai; Shanghai Health Academic Leader Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18